Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fees Must Be Considered Due To Ballooning ANDAs – FDA’s Galson

Executive Summary

The "exponential" growth of ANDA submissions necessitates an examination of user fees for generic applications, Center for Drug Evaluation & Research Director Steven Galson told the Generic Pharmaceutical Association's Fall Technical Conference Oct. 24
Advertisement

Related Content

FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins
FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins
Citizen Petition Reform Proposals Include User Fees, Payments For Lost Profits
FDA Expecting 43% Increase In ANDA Submissions For FY 2005
FDA Expecting 43% Increase In ANDA Submissions For FY 2005

Topics

Advertisement
UsernamePublicRestriction

Register

PS046489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel